Excipientes

CAPTEX 300 LOW C6 EP/NF/JPE increase solubility and bioavailability of API. Medium-Chain Triglycerides EP; Medium-Chain Triglycerides USP/NF; Medium-Chain Fatty acid Triglycerides JPE

CAPTEX 8000 increase solubility and bioavailability of API. Medium-Chain (fatty acid) Triglyceride JPE; Glycerol Esters of fatty acid JSFA, Tricaprylin

QA Captex 355 EP/NF/JPE increase solubility and bioavailability of API. Medium-CHAIN: Triglycerides EP; Medium-Chain Triglycerides USP/NF; Medium-Chain Fatty Acid Triglyceride JPE.

Sheffied Tabletting System Disintequik MCC 25 is a co-processed excipient consisting of 75% Alpha monohydrate lactose and 25% Microcrystalline Cellulose (MCC). The processing results in a co-agglomeration compound of the two ingredients, spray dried lactose and MCC, preserving the identity of each component. Prior to processing, both ingredients meet all of the requirements as outlined in the current monographs of the EU, JP and NF. Disintequick MCC 25 reduces raw materials QC Testing, Manufacturing Steps and process validation. A Drug Master File is available. Added benefits include: reduction of blending issues, low dust generation, the avoidance of costly wet granulation processes, improved flowability and content uniformity during compression.